A Potential Breakthrough in Cardiovascular Treatment form Eli Lilly
A new experimental drug developed by Eli Lilly, lepodisiran, is showing promising results in reducing the risk of genetically inherited heart disease. This development marks a significant milestone in cardiovascular medicine, as lepodisiran specifically targets lipoprotein(a), or Lp(a), a key risk factor for heart disease that has long been difficult to address. Unlike traditional cholesterol-lowering…








